Cellectis (CLLS) Capital Expenditures (QoQ) (2015 - 2026)
Cellectis (CLLS) Capital Expenditures (QoQ) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -106.25% |
| Dec 31, 2025 | 459.10% |
| Sep 30, 2025 | -287.21% |
| Jun 30, 2025 | 22.78% |
| Mar 31, 2025 | -108.56% |
| Dec 31, 2024 | 694.08% |
| Sep 30, 2024 | 25.14% |
| Jun 30, 2024 | -376.15% |
| Mar 31, 2024 | -111.66% |
| Dec 31, 2023 | 695.54% |
| Sep 30, 2023 | -16.30% |
| Jun 30, 2023 | -26.76% |
| Mar 31, 2023 | -104.82% |
| Dec 31, 2022 | 1,086.61% |
| Sep 30, 2022 | 51.04% |
| Jun 30, 2022 | -46.17% |
| Mar 31, 2022 | -101.70% |
| Dec 31, 2021 | 897.68% |
| Sep 30, 2021 | 15.36% |
| Jun 30, 2021 | 33.46% |